D.A. Gros is Co-Founder, Chief Executive Officer and Chairman of the Board of Imbria Pharmaceuticals. Prior to founding Imbria, Dr. Gros was President, Chief Operating Officer and acting Chief Financial Officer at Neurocrine Biosciences, Inc. Before Neurocrine, he served as Chief Business Officer and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and as Chief Strategy Officer of Sanofi S.A. Prior to joining Sanofi, Dr. Gros held positions of increasing responsibility with a focus on biotechnology and pharmaceuticals in investment banking at both Centerview Partners LLC and Merrill Lynch, Pierce, Fenner & Smith, Inc., and in management consulting at McKinsey & Company.
Dr. Gros also co-founded and currently serves on the Board of Directors of Eliem Therapeutics, Inc. He holds an MD from Johns Hopkins University School of Medicine, an MBA from Harvard Business School, and an AB from Dartmouth College.